TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02134704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data recording with all sensors
Description: The sensors will be placed in the child body and will allow the collection of all the data of the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data recording with all sensors
Description: The sensors will be placed in the child body and will allow the collection of all the data of the trial.
Study: NCT00957346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone+misoprostol
Description: single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+Misoprostol
Description: placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
Study: NCT02647047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
Study: NCT04277572

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Aortic valve surgery
Study: NCT01168804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine plus bortezomib plus dexamethasone
Description: Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
Study: NCT04920461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additional MRI sequences
Description: Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: Neurovisual function assessed with neuropsychological tests
Study: NCT03545152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New life-style
Description: Combination of exercise and cognitive interventions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New life-style
Description: Combination of exercise and cognitive interventions
Study: NCT02221739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT03816137

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mosaic SOSIPs
Description: Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mosaic SOSIPs
Description: Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study: NCT02221739

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (IMRT or 3-D CRT)
Study: NCT01285921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular test before and after hippocampal surgery
Description: * Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~* HIT (testing semicircular canal function at high frequency).Results: Gain in %~* VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~* ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~* Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S
Study: NCT02807116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Subjects received a single oral 400-mg dose of pacritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
Study: NCT01562873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT02807116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib and Rifampin
Description: On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
Study: NCT02287792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18-FDG PET/CT scan
Description: Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
Study: NCT01220310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online diabetes workshop observation and learning sessions
Description: We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
Study: NCT01720511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Purple Rice
Description: Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
Study: NCT00615082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Education & Social Support
Description: An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
Study: NCT01720511

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brown Rice
Description: Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
Study: NCT02887105

Intervention type: OTHER
Intervention: Standard neuropsychological assessment

Intervention type: OTHER
Intervention: Brain MRI
Study: NCT03816137

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mosaic SOSIPs
Description: Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study: NCT02129569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Description: Receive information about strategies for cognitive self-management of distress
Study: NCT00163553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pethidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02060396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: One tablet of Adiro 100 mg will be administered daily orally for 7 days.
Study: NCT06320197

Intervention type: OTHER
Intervention: In situ simulation assessment
Description: Unannounced in situ simulation assessment during working hours

Intervention type: OTHER
Intervention: In situ simulation assessment
Description: Unannounced in situ simulation assessment during working hours
Study: NCT01797783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A multifocal contact lens with comfort additive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A multifocal contact lens
Study: NCT03807999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study: NCT02075255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 24 inclusive.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
Study: NCT02463266

Intervention type: BEHAVIORAL
Intervention: SUSTAIN Monitoring and Care Management
Description: Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
Study: NCT04742517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1128
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1128
Description: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study: NCT02853331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Oral capsule
Study: NCT03464097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days
Study: NCT03464097

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT00590681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Temozolomide
Description: This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
Study: NCT02378428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIBG
Study: NCT04452526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care
Study: NCT01369485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (VERV™ System)
Description: Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham version of (VERV™ System)
Description: Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
Study: NCT05832476

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03338309

Intervention type: OTHER
Intervention: Instantaneous wave-free ratio measurement
Description: Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
Study: NCT00622076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative catheterization
Description: postoperative catheterization after anterior colporrhaphy for five days versus two days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative catheterization
Description: postoperative catheterization after anterior colporrhaphy for five days versus two days.
Study: NCT00882492

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GLP 1
Description: This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline solution placebo
Description: This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
Study: NCT03920384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental intervention arm
Description: Psychological therapy for psychosis with new therapy components

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control arm
Description: Standard psychological therapy for psychosis without new therapy components
Study: NCT01609101

Intervention type: DEVICE
Group type: OTHER
Intervention: C-MAC ® videolaryngoscope
Description: C-MAC ® videolaryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: Coopdech® videolaryngoscope
Description: Coopdech® videolaryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: McGrath® Series 5 videolaryngoscope
Description: McGrath® Series 5 videolaryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: Glidescope® Cobalt videolaryngoscope
Description: Glidescope® Cobalt videolaryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: King Vision® videolaryngoscope
Description: King Vision® videolaryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: Venner® videolaryngoscope
Description: Venner® videolaryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: McGrath® MAC
Description: McGrath® MAC (Aircraft Medical, Edinburgh, UK)
Study: NCT05034445

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
Study: NCT02142114

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye injection by 30 or 32 gauge needle
Description: Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
Study: NCT00905008

Intervention type: PROCEDURE
Intervention: transluminal percutaneous coronary intervention
Description: All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis \<30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.

Intervention type: DEVICE
Intervention: Drug-Eluting and Bare-Metal stents
Description: Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents

Intervention type: DEVICE
Intervention: Drug-Eluting and Bare-Metal stents
Description: Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
Study: NCT02129569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Receive individualized walking prescription and wear pedometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Receive supplemental counseling support over the phone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive NCI educational booklets and a link to the ACS website

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telephone-based intervention
Description: Receive calls that are primarily social in nature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01347645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7820
Description: Test product: dose and mode of administration:~E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.~The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle).
Study: NCT02143531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg of Ondansetron IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg of Haloperidol IV
Study: NCT00908856

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow mononuclear cell transfusion
Description: a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
Study: NCT03816137

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mosaic SOSIPs
Description: Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mosaic SOSIPs
Description: Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 763 SOSIP
Description: HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study: NCT02638428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CancerSCAN™
Description: Targeted deep sequencing